Alpha emitters are radionuclides with good pharmacological characteristics for the treatment
of cancer because they decay by emitting high linear energy transfer particles. Recent …

Monoclonal antibodies and antibody fragments have proven to be highly effective vectors for
the delivery of radionuclides to target tissues for positron emission tomography (PET) and …

For the integration of targeted diagnosis and treatment of tumor, we innovatively designed
and synthesized a single-molecule hetero-multinuclear Er (III)–Cu (II) complex (ErCu 2) and …

With the increasing use of antibody therapeutics, clinicians are faced with challenges of
precisely stratifying patients and promptly assessing response to treatment. Antibody …

Purpose Trophoblast glycoprotein, the so-called 5T4, is an oncofetal antigen expressed in
many different cancers. However, no 5T4-specific radioligand is employed in the clinic for …

Astatine-211 (211At) has emerged as a promising radionuclide for targeted alpha therapy of
cancer by virtue of its favorable nuclear properties. However, the limited in vivo stability of …

211At, when coupled to a targeting agent, is one of the most promising radionuclides for
therapeutic applications. The main labelling approach consists in the formation of astatoaryl …

Introduction Single domain antibody fragments (sdAbs) are an appealing scaffold for
radiopharmaceutical development due to their small size (~ 15 kDa), high solubility, high …

Background 211At-radiopharmaceuticals are currently the subject of growing studies for
targeted alpha therapy of cancers, which leads to the widening of the scope of the targeting …

Radiotheranostics utilizes a set of radioligands incorporating diagnostic or therapeutic
radionuclides to achieve both diagnosis and therapy. Imaging probes using diagnostic …